TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

TROPHAMINE

AMINO ACIDS
Metabolic Approved 1984-07-20
1
Indication
--
Phase 3 Trials
41
Years on Market

Details

Status
Prescription
First Approved
1984-07-20
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

Active Ingredient: AMINO ACIDS

TROPHAMINE Approval History

Loading approval history...

What TROPHAMINE Treats

2 indications

TROPHAMINE is approved for 2 conditions since its original approval in 1984. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Weight Loss
  • Negative Nitrogen Balance
Source: FDA Label

Drugs Similar to TROPHAMINE

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

TROPHAMINE FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

TrophAmine® is indicated for the nutritional support of infants (including those of low birth weight) and young pediatric patients requiring TPN via either central or peripheral infusion routes. Parenteral nutrition with TrophAmine® is indicated to prevent nitrogen and weight loss or treat negative nitrogen balance in infants and young pediatric patients where the alimentary tract, by the oral, gastrostomy, or jejunostomy route, cannot or should not be used, or adequate protein intake is not feasible by these routes; gastrointestinal absorption of protein is impaired; or protein requirements a...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.